论文部分内容阅读
[目的]对患有胃溃疡的患者采用拉呋替丁胶囊治疗的临床效果及安全性分析。[方法]选取在我院接受治疗的80例胃溃疡患者作为研究对象,将其平均分为试验组和对照组,对照组患者采用克拉霉素+甲硝唑+兰索拉唑治疗,试验组患者采用克拉霉素+甲硝唑+拉呋替丁胶囊治疗。对比分析两组不良反应、治疗效果以及症状评分情况。[结果]试验组研究对象的总有效率(97.50%)与对照组研究对象的总有效率(63.50%)相比明显较高,差异有统计学意义(χ2=16.9747,P<0.01)。试验组治疗后症状评分(57±9.9)与对照组治疗后症状评分(68±9.5)相比明显较低,差异有统计学意义(t=5.0704,P<0.01)。试验组不良反应发生率(5.00%)与对照组不良反应发生率(32.50%)相比明显较低,差异有统计学意义(χ2=9.92821,P<0.01)。[结论]采用克拉霉素+甲硝唑+拉呋替丁胶囊对胃溃疡的患者治疗效果显著,改善患者症状,降低不良反应,安全性较高,值得推广应用。
[Objective] To evaluate the clinical efficacy and safety of lafutidine capsule in patients with gastric ulcer. [Method] Eighty patients with gastric ulcer who were treated in our hospital were selected as the research object, divided equally into the experimental group and the control group, the control group treated with clarithromycin + metronidazole + lansoprazole, the experimental group Patients with clarithromycin + metronidazole + lafutidine capsule treatment. Comparative analysis of two groups of adverse reactions, treatment and symptom score. [Results] The total effective rate (97.50%) in the experimental group was significantly higher than that in the control group (63.50%), with significant difference (χ2 = 16.9747, P <0.01). Symptom score (57 ± 9.9) in the experimental group was significantly lower than that in the control group after treatment (68 ± 9.5), the difference was statistically significant (t = 5.0704, P <0.01). The adverse reaction rate (5.00%) in the experimental group was significantly lower than that in the control group (32.50%) (χ2 = 9.92821, P <0.01). [Conclusion] The use of clarithromycin + metronidazole + lafutidine capsules has significant therapeutic effect on patients with gastric ulcer, which can improve the symptoms and reduce the adverse reactions of patients with high safety and is worth popularizing and applying.